Novartis takes on Sanofi, Amgen with $9.7-bn takeover of heart drug maker

Topics Novartis | Sanofi

Swiss drugmaker Novartis is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co as it challenges cardiovascular medicines from Amgen Inc, Sanofi and Regeneron Pharmaceuticals. Novartis is paying $85 per share in cash, a 24% premium over The Medicines Co's closing price of $68.

55 on Friday, to acquire the U.S. biotechnology company's lone drug, the cholesterol-lowering injection inclisiran. The deal shows Novartis CEO Vas Narasimhan is ready to spend billions on not just rare disease treatments,.....

This article is no longer available in our repository.

There could be multiple reasons for this.